private:integrateddiagnostics
|
1655330
|
Mar 9th, 2018 12:00AM
|
Indi (Integrated Diagnostics)
|
856
|
43.00
|
Open
|
Biotechnology
|
Mar 9th, 2018 12:34PM
|
Mar 9th, 2018 12:34PM
|
|
Open
|
|
|
|
|
|
|
|
|
Integrated Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
private:integrateddiagnostics
|
1655330
|
Feb 17th, 2018 12:00AM
|
Indi (Integrated Diagnostics)
|
855
|
42.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.
The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com
|
|
|
|
|
|
|
|
|
|
Integrated Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
private:integrateddiagnostics
|
1655330
|
Feb 16th, 2018 12:00AM
|
Indi (Integrated Diagnostics)
|
855
|
42.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.
The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com
|
|
|
|
|
|
|
|
|
|
Integrated Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
private:integrateddiagnostics
|
1655330
|
Feb 15th, 2018 12:00AM
|
Indi (Integrated Diagnostics)
|
855
|
42.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.
The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com
|
|
|
|
|
|
|
|
|
|
Integrated Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
private:integrateddiagnostics
|
1655330
|
Feb 14th, 2018 12:00AM
|
Indi (Integrated Diagnostics)
|
855
|
42.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.
The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com
|
|
|
|
|
|
|
|
|
|
Integrated Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
private:integrateddiagnostics
|
1655330
|
Feb 13th, 2018 12:00AM
|
Indi (Integrated Diagnostics)
|
855
|
42.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.
The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com
|
|
|
|
|
|
|
|
|
|
Integrated Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
private:integrateddiagnostics
|
1655330
|
Feb 12th, 2018 12:00AM
|
Indi (Integrated Diagnostics)
|
855
|
42.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.
The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com
|
|
|
|
|
|
|
|
|
|
Integrated Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
private:integrateddiagnostics
|
1655330
|
Feb 11th, 2018 12:00AM
|
Indi (Integrated Diagnostics)
|
855
|
42.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.
The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com
|
|
|
|
|
|
|
|
|
|
Integrated Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
private:integrateddiagnostics
|
1655330
|
Feb 10th, 2018 12:00AM
|
Indi (Integrated Diagnostics)
|
855
|
42.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.
The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com
|
|
|
|
|
|
|
|
|
|
Integrated Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
private:integrateddiagnostics
|
1655330
|
Feb 9th, 2018 12:00AM
|
Indi (Integrated Diagnostics)
|
855
|
42.00
|
Open
|
Biotechnology
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with non-invasive blood tests. Our first test, Xpresys Lung, is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.
The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at www.indidx.com
|
|
|
|
|
|
|
|
|
|
Integrated Diagnostics
|
Health Care
|
Health Care Equipment & Services
|